Ionis Pharmaceuticals Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View analyst ratings for Ionis Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Ionis Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ionis Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Ionis Pharmaceuticals saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 8,970,000 shares, a decrease of 17.3% from the May 31st total of 10,850,000 shares. Based on an average daily volume of 1,820,000 shares, the short-interest ratio is currently 4.9 days. Currently, 6.7% of the shares of the company are short sold.
View Ionis Pharmaceuticals' Short Interest.

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Ionis Pharmaceuticals.

Ionis Pharmaceuticals will be holding an earnings conference call on Wednesday, August 4th at 11:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.16. The firm had revenue of $112 million for the quarter, compared to analysts' expectations of $134.93 million. Ionis Pharmaceuticals had a negative net margin of 69.63% and a negative trailing twelve-month return on equity of 41.74%. Ionis Pharmaceuticals's revenue was down 15.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.35) EPS.
View Ionis Pharmaceuticals' earnings history.

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, IONS stock has decreased by 22.6% and is now trading at $38.03.
View which stocks have been most impacted by COVID-19.

Ionis Pharmaceuticals updated its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $600 M-, compared to the consensus revenue estimate of $632.68 million.

15 brokerages have issued 12 month target prices for Ionis Pharmaceuticals' stock. Their forecasts range from $33.00 to $86.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $57.86 in the next twelve months. This suggests a possible upside of 52.2% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of IONS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IONS stock can currently be purchased for approximately $38.03.

Ionis Pharmaceuticals has a market capitalization of $5.36 billion and generates $729 million in revenue each year. The company earns $-451,290,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis.

Ionis Pharmaceuticals employs 147,000 workers across the globe.

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

Ionis Pharmaceuticals is headquartered at 2855 GAZELLE COURT, CARLSBAD CA, 92010.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at (760) 931-9200 or via email at [email protected]